Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 2Multiple Myeloma 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × obatoclax × Clear all
NCT00719901 2015-01-12

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
11 enrolled 9 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡